Serina Therapeutics, Inc.
SER
$5.65
$0.152.73%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 154.90% | -- | -100.45% | -51.72% | 628.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.90% | -- | -100.45% | -51.72% | 628.57% |
| Cost of Revenue | 97.74% | 166.82% | 160.75% | 300.50% | 232.78% |
| Gross Profit | -95.85% | -168.03% | -209.13% | -318.29% | -226.91% |
| SG&A Expenses | 9.47% | 138.28% | 398.24% | 227.45% | 391.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.39% | 151.85% | 225.50% | 256.97% | 311.45% |
| Operating Income | -43.95% | -152.39% | -321.36% | -263.09% | -309.10% |
| Income Before Tax | -224.82% | 67.89% | -361.85% | -21.06% | 540.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -224.82% | 67.89% | -361.85% | -21.06% | 540.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -48.15% | -- | -- | -- | -- |
| Net Income | -223.90% | 67.95% | -360.70% | -19.52% | 544.06% |
| EBIT | -43.95% | -152.39% | -321.36% | -263.09% | -309.10% |
| EBITDA | -45.68% | -154.40% | -317.61% | -273.03% | -310.45% |
| EPS Basic | -207.36% | 90.83% | -235.74% | -80.09% | 64.30% |
| Normalized Basic EPS | -204.98% | 82.81% | -136.96% | 140.93% | 274.74% |
| EPS Diluted | -229.41% | 90.83% | -293.31% | -43.48% | 356.99% |
| Normalized Diluted EPS | -225.25% | 82.81% | -203.60% | 216.76% | 601.09% |
| Average Basic Shares Outstanding | 17.50% | 249.68% | 668.49% | 304.16% | 291.99% |
| Average Diluted Shares Outstanding | -1.51% | 249.68% | 174.20% | 41.76% | 36.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |